BIRC7 Antikörper (AA 101-200)
Kurzübersicht für BIRC7 Antikörper (AA 101-200) (ABIN672561)
Target
Alle BIRC7 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 101-200
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Homologie
- Dog,Cow
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human Livin
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
-
Haltbarkeit
- 12 months
-
-
-
: "Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin." in: PLoS ONE, Vol. 16, Issue 1, pp. e0245581, (2021) (PubMed).
: "Prospective experimental studies on the renal protective effect of ulinastatin after paraquat poisoning." in: World journal of emergency medicine, Vol. 3, Issue 4, pp. 299-304, (2014) (PubMed).
-
: "Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin." in: PLoS ONE, Vol. 16, Issue 1, pp. e0245581, (2021) (PubMed).
-
- BIRC7 (Baculoviral IAP Repeat-Containing 7 (BIRC7))
-
Andere Bezeichnung
- Livin
-
Hintergrund
-
Synonyms: KIAP, LIVIN, MLIAP, RNF50, ML-IAP, Baculoviral IAP repeat-containing protein 7, Kidney inhibitor of apoptosis protein, Melanoma inhibitor of apoptosis protein, RING finger protein 50, BIRC7, UNQ5800/PRO19607/PRO21344
Background: Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing.
-
Gen-ID
- 79444
-
UniProt
- Q96CA5
Target
-